These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

262 related articles for article (PubMed ID: 36693762)

  • 21. Locked vs. unlocked nucleic acids (LNA vs. UNA): contrasting structures work towards common therapeutic goals.
    Campbell MA; Wengel J
    Chem Soc Rev; 2011 Dec; 40(12):5680-9. PubMed ID: 21556437
    [TBL] [Abstract][Full Text] [Related]  

  • 22. The Evolution of Antisense Oligonucleotide Chemistry-A Personal Journey.
    Agrawal S
    Biomedicines; 2021 May; 9(5):. PubMed ID: 34063675
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Nano drug delivery systems for antisense oligonucleotides (ASO) therapeutics.
    Ramasamy T; Ruttala HB; Munusamy S; Chakraborty N; Kim JO
    J Control Release; 2022 Dec; 352():861-878. PubMed ID: 36397636
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Advances in quantitative bioanalysis of oligonucleotide biomarkers and therapeutics.
    Wang L; Ji C
    Bioanalysis; 2016; 8(2):143-55. PubMed ID: 26652713
    [TBL] [Abstract][Full Text] [Related]  

  • 25. [Study toward practical use of oligonucleotide therapeutics].
    Inoue T; Yoshida T
    Kokuritsu Iyakuhin Shokuhin Eisei Kenkyusho Hokoku; 2014; (132):13-5. PubMed ID: 25707197
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Antisense technology: an overview and prospectus.
    Crooke ST; Baker BF; Crooke RM; Liang XH
    Nat Rev Drug Discov; 2021 Jun; 20(6):427-453. PubMed ID: 33762737
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Meeting report: oligonucleotide ADME workshop.
    Hood S; Kenworthy D; Christensen JK
    Xenobiotica; 2022 Aug; 52(8):957-961. PubMed ID: 36093882
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Delivery of oligonucleotides with lipid nanoparticles.
    Wang Y; Miao L; Satterlee A; Huang L
    Adv Drug Deliv Rev; 2015 Jun; 87():68-80. PubMed ID: 25733311
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Oligonucleotides as therapeutic tools for brain disorders: Focus on major depressive disorder and Parkinson's disease.
    Bortolozzi A; Manashirov S; Chen A; Artigas F
    Pharmacol Ther; 2021 Nov; 227():107873. PubMed ID: 33915178
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Liver as a target for oligonucleotide therapeutics.
    Sehgal A; Vaishnaw A; Fitzgerald K
    J Hepatol; 2013 Dec; 59(6):1354-9. PubMed ID: 23770039
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Impurities in Oligonucleotide Drug Substances and Drug Products.
    Capaldi D; Teasdale A; Henry S; Akhtar N; den Besten C; Gao-Sheridan S; Kretschmer M; Sharpe N; Andrews B; Burm B; Foy J
    Nucleic Acid Ther; 2017 Dec; 27(6):309-322. PubMed ID: 29125795
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Is there a future for cell-penetrating peptides in oligonucleotide delivery?
    Lee SH; Castagner B; Leroux JC
    Eur J Pharm Biopharm; 2013 Sep; 85(1):5-11. PubMed ID: 23958313
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Recommendations of the Oligonucleotide Safety Working Group's Formulated Oligonucleotide Subcommittee for the Safety Assessment of Formulated Oligonucleotide-Based Therapeutics.
    Marlowe JL; Akopian V; Karmali P; Kornbrust D; Lockridge J; Semple S
    Nucleic Acid Ther; 2017 Aug; 27(4):183-196. PubMed ID: 28609186
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Recent advances in the medicinal chemistry of antisense oligonucleotides.
    Uhlmann E
    Curr Opin Drug Discov Devel; 2000 Mar; 3(2):203-13. PubMed ID: 19649851
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Applications of mass spectrometry to the study of siRNA.
    Beverly MB
    Mass Spectrom Rev; 2011; 30(6):979-98. PubMed ID: 20201110
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Innovative developments and emerging technologies in RNA therapeutics.
    Halloy F; Biscans A; Bujold KE; Debacker A; Hill AC; Lacroix A; Luige O; Strömberg R; Sundstrom L; Vogel J; Ghidini A
    RNA Biol; 2022; 19(1):313-332. PubMed ID: 35188077
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Medicinal chemistry: The key to critical thinking in pharmacotherapy.
    Wall W; Pamulapati LG; Koenig RA; Dukat M; Caldas LM
    Curr Pharm Teach Learn; 2022 Mar; 14(3):253-257. PubMed ID: 35307082
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Modulation of RNA Splicing by Oligonucleotides: Mechanisms of Action and Therapeutic Implications.
    Sergeeva OV; Shcherbinina EY; Shomron N; Zatsepin TS
    Nucleic Acid Ther; 2022 Jun; 32(3):123-138. PubMed ID: 35166605
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Oligonucleotides for upregulating gene expression.
    Khorkova O; Hsiao J; Wahlestedt C
    Pharm Pat Anal; 2013 Mar; 2(2):215-29. PubMed ID: 24237027
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Current progress on aptamer-targeted oligonucleotide therapeutics.
    Dassie JP; Giangrande PH
    Ther Deliv; 2013 Dec; 4(12):1527-46. PubMed ID: 24304250
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 14.